Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Blood (2007) 109 (11): 4686–4692.

https://doi.org/10.1182/blood-2006-11-055186

Published: 2007

Includes: Supplemental data

Journal Articles

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Martin C. Müller, MD, Philipp Erben, MD, Thomas Schenk, MD, Stephanie Lauber, MD, Jens Kruth, MD, Jana Hoffmann, Thomas Ernst, MD, Tanja Lahaye, MD, Georgia Metzgeroth, MD, Michael Acevedo, PhD, Claude Nicaise, MD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 748.

https://doi.org/10.1182/blood.V108.11.748.748

Published: 2006

Journal Articles

Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib.

Alice Fabarius, PhD, Michelle Giehl, Alwin Kraemer, MD, Oliver Frank, PhD, Martin C. Mueller, MD, Peter Duesberg, PhD, Tanja Lahaye, MD, Claudia Schoch, MD, Rudiger Hehlmann, MD, Wolfgang Seifarth, PhD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 2167.

https://doi.org/10.1182/blood.V108.11.2167.2167

Published: 2006

Journal Articles

BCR-ABL P-Loop Deletion Detected in Imatinib-Resistant CML Patients Corresponds to Splice Variant Associated with L248V Point Mutation, Retains BCR-ABL Kinase Activity, and Responds to Dasatinib Treatment.

Nikolas von Bubnoff, MD, Philipp Erben, MD, Martin Müller, MD, Tanja Lahaye, MD, Susanne Schnittger, MD, Frank Schlegel, MD, Hubert Serve, MD, Andreas Grüneisen, MD, Rudiger Hehlmann, MD, Christian Peschel, MD, Justus Duyster, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 2168.

https://doi.org/10.1182/blood.V108.11.2168.2168

Published: 2006

Journal Articles

Dynamics of Cytogenetic Aberrations in Philadelphia Chromosome Positive and Negative Hematopoiesis during Dasatinib Therapy of Chronic Myeloid Leukemia Patients after Imatinib Failure.

Alice Fabarius, PhD, Claudia Schoch, MD, Martin C. Mueller, MD, Philipp Erben, MD, Tanja Lahaye, MD, Michelle Giehl, Oliver Frank, PhD, Wolfgang Seifarth, PhD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 2114.

https://doi.org/10.1182/blood.V108.11.2114.2114

Published: 2006

Journal Articles

Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia.

Stefan Fruehauf, MD, Julian Topaly, MD, Eike C. Buss, MD, Tanja Lahaye, MD, Oliver G. Ottmann, MD, Thomas Fischer, MD, Bertold Emmerich, MD, Ulrike Haus, Rudiger Hehlmann, MD, Anthony D. Ho, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 1105.

https://doi.org/10.1182/blood.V106.11.1105.1105

Published: 2005

Journal Articles

Iron Deficiency Status in Polycythemia Vera Correlates Well with Bone Marrow Angiogenesis in Patients Treated with Phlebotomy.

Andreas Willer, MD, Tanja Lahaye, MD, Susanne Saussele, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2004) 104 (11): 4763.

https://doi.org/10.1182/blood.V104.11.4763.4763

Published: 2004

Journal Articles

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

Andreas Burchert, Stefan Wölfl, Manuel Schmidt, Cornelia Brendel, Barbara Denecke, Dali Cai, Larissa Odyvanova, Tanja Lahaye, Martin C. Müller, Thomas Berg, Harald Gschaidmeier, Burghardt Wittig, Rüdiger Hehlmann, Andreas Hochhaus, Andreas Neubauer

Blood (2003) 101 (1): 259–264.

https://doi.org/10.1182/blood-2002-02-0659

Published: 2003

Journal Articles

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

Tim H. Brümmendorf, Inci Ersöz, Ulrike Hartmann, Kerol Bartolovic, Stefan Balabanov, Alexandra Wahl, Peter Paschka, Sebastian Kreil, Tanja Lahaye, Ute Berger, Harald Gschaidmeier, Carsten Bokemeyer, Rüdiger Hehlmann, Klaus Dietz, Peter M. Lansdorp, Lothar Kanz, Andreas Hochhaus

Blood (2003) 101 (1): 375.

https://doi.org/10.1182/blood-2002-08-2557

Published: 2003

NARROW

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Centrosome Aberrations, Disturbed Mitotic Spindle Formation and G1 Arrest in Normal and Leukemic Cells Treated with the SRC/ABL Inhibitor Dasatinib.

BCR-ABL P-Loop Deletion Detected in Imatinib-Resistant CML Patients Corresponds to Splice Variant Associated with L248V Point Mutation, Retains BCR-ABL Kinase Activity, and Responds to Dasatinib Treatment.

Dynamics of Cytogenetic Aberrations in Philadelphia Chromosome Positive and Negative Hematopoiesis during Dasatinib Therapy of Chronic Myeloid Leukemia Patients after Imatinib Failure.

Combination Treatment with Imatinib and Mitoxantrone/Etoposide Is a Suitable Preparative Regimen before Allogeneic Transplantation in Patients with Myeloid Blast Crisis of Chronic Myeloid Leukemia.

Iron Deficiency Status in Polycythemia Vera Correlates Well with Bone Marrow Angiogenesis in Patients Treated with Phlebotomy.

Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only